Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations
HU Meier-Kriesche, B Kaplan - Clinical Therapeutics, 2000 - Elsevier
BACKGROUND: Sirolimus is a novel macrolide immunosuppressive drug with a mechanism
of action distinct from that of both cyclosporine and tacrolimus. Recent clinical studies have
demonstrated a decrease in acute rejection episodes in renal transplant patients receiving
sirolimus compared with controls. The major toxicities associated with sirolimus treatment
are thrombocytopenia and hyperlipidemia. In addition, concern has been raised by the
higher serum creatinine levels noted in patients receiving sirolimus and cyclosporine …
of action distinct from that of both cyclosporine and tacrolimus. Recent clinical studies have
demonstrated a decrease in acute rejection episodes in renal transplant patients receiving
sirolimus compared with controls. The major toxicities associated with sirolimus treatment
are thrombocytopenia and hyperlipidemia. In addition, concern has been raised by the
higher serum creatinine levels noted in patients receiving sirolimus and cyclosporine …